A Phase 3 interventional study of Abatacept and Placebo in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-23.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 17th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 270 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 18th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 22 in phase 3, and was the 19th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abatacept
Drug: Placebo
Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
Also known as: Orencia, BMS-188667
Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169
Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using an enzyme-linked immunosorbent assay (ELISA). Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
Time frame: Day 169
Re-introduction (RI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Groups
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
Time frame: Day 253 (short term)
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Day 253, by DBW Period Placebo Group
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
Time frame: Day 253 (short term)
Lead-in (LI) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
Time frame: For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
LI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by Electrochemiluminescence (ECL) Over Time
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
Time frame: For on-treatment visits: Day 1-Day 85, includes ≤21 Days after last dose or up to 1st dose of DBW Period. For follow-up post visits for participants who discontinued drug in LI: Day 22 after last dose of drug to Day 85 after last dose of drug
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. Samples were obtained during treatment (TRT) visits.
Time frame: Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA at Post Visits
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
Time frame: Day 22 after last dose of drug to Day 85 after last dose of drug
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
Time frame: Days 86-169, includes ≤21 Days after last dose or up to 1st dose of RI Period
DBW Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL At Post Visits
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
Time frame: Day 22 after last dose of drug to Day 85 after last dose of drug
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ELISA Over Time by DBW Treatment Group
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
Time frame: For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
RI Period; Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses by ECL Over Time by DBW Treatment Group
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
Time frame: For on-treatment visits: Days 170-253, includes ≤21 Days after last dose or up to 1st dose of LTE Period. For follow-up post visits for participants who discontinued drug in RI: Day 22 after last dose of drug to Day 85 after last dose of drug
Short Term (ST); Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ELISA Antibody Responses by DBW Treatment Groups
Serum samples from Abatacept-treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. ST was defined as the LI Period, the DBW Period, and the RI Period (Days 1-253).
Time frame: For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
Short Term: Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 ECL Antibody Responses by DBW Treatment Groups
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
Time frame: For on-TRT visits: Days 1-253 (ST). For follow-up post visits for participants who discontinued drug in the ST: Day 22 after last dose of ST drug to Day 85 after last dose of ST drug
Short Term: Mean Change in Disease Activity Score (DAS) 28 (Using C-Reactive Protein [CRP]) From Baseline Over Time by DBW Treatment Groups
The DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
Time frame: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
Short Term: Percentage of Participants Achieving Clinically Meaningful Improvement (CMI) in DAS 28 (CRP), Low Disease Activity (LDAS), or Clinical Remission Over Time by DBW Treatment Groups
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
Time frame: Days 85, 169, and 253 (short term)
Short Term; Mean Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Baseline Over Time by DBW Treatment Groups
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.
Time frame: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
Short Term; Percentage of Participants With HAQ-DI Response Over Time by DBW Treatment Groups
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.
Time frame: Days 1 (Baseline),15, 29, 57, 78, 85, 113, 141, 169, 197, 225, and 253 (short term)
LI; Mean Change in DAS 28 (CRP) From Baseline Over Time
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
Time frame: Days 1 (Baseline), 15, 29, 57, 78, 85
LI; Percentage of Participants With Clinically Meaningful Improvement in DAS (CRP) Over Time
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
Time frame: Days 15, 29, 57, 78, 85
DBW Period; Mean Change in DAS 28 (CRP) From DBW Period Baseline (Day 85) Over Time
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
Time frame: Days 85 (Period 2 Baseline), 113, 141, and 169
DBW Period; Percentage of Participants With Rheumatoid Arthritis (RA) Flare Over Time
A participant had an RA flare if at least 2 of the following criteria were met: * Doubling of tender and swollen joint count from Day 78 * Increase in DAS28-CRP score ≥ 1.2 from Day 78 * Prematurely discontinued from Double-blind Withdrawal Period (Period 2) and continued to Re-introduction Period (Period 3)
Time frame: Days 85, 113, 141, and 169
RI Period; Mean Change in DAS 28 (CRP) From RI Period Baseline (Day 169) Over Time
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
Time frame: Days 169 (Period III Baseline), 197, 225, and 253
LI; Number of Participants With Deaths, Serious Adverse Events (SAEs), SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to Discontinuation
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
LI Period; Number of Participants With AEs of Special Interest
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
LI; Number of Participants With Hematology Values Meeting the Marked Abnormality (MA) Criteria
Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/ microliter (uL); eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
LI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
LI; Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
LI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*upper limits of normal (ULN),or if BL\< lower limits of normal (LLN) then use 0.8\*BL or \> upper limits of normal (ULN),or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>ULN,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis: Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells (RBCs), White Blood Cells (WBCs):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
Time frame: From Day 1 through Day 85, up to 56 days post last dose in Lead-in Period or up to first dose in next period, whichever occurred earlier
LI Period; Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Blood pressure was taken in participants while seated and measured in millimeters of mercury (mmHg). Pressures were assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
Time frame: Days 1, 15, 29, 57, 78, and 85
LI Period; Mean Heart Rate (HR)
Heart rate was taken in participants while seated and measured in beats per minute (bpm). Heart rate was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
Time frame: Days 1, 15, 29, 57, 78, and 85
LI Period; Mean Temperature (T)
Temperature was taken in participants while seated and measured in degrees celsius. Temperature was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
Time frame: Days 1, 15, 29, 57, 78, and 85
DBW; Number of Participants With Death, Serious SAEs, Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
DBW; Number of Participants With AEs of Special Interest
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
DBW; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
DBW; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
DBW; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
DBW; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
Time frame: From Day 85 through Day 169, up to 56 days post last dose in DBW Period or up to first dose in RI Period, whichever occurred earlier
DBW; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Double Blind Period
Blood pressures were taken in participants while seated, just prior to study drug injection, and measured in millimeters of mercury (mmHg).
Time frame: Days 113, 141, and 169
DBW Period; Mean Heart Rate (HR) During Period 2
Heart Rate was taken in participants while seated, just prior to study drug injection, and measured in beats per minute (bpm)
Time frame: Days 113, 141, and 169
DBW Period; Mean Temperature (T) During Period II
Participants were seated and temperature taken just prior to study drug injection.
Time frame: Days 113, 141, and 169
RI; Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, AEs, Related AEs, or AEs Leading to Discontinuation
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
RI; Number of Participants With AEs of Special Interest
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
RI; Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
RI; Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
RI; Number of Participants With Electrolytes Values Meeting the Marked Abnormality Criteria
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
RI; Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
Time frame: From Day 169 through Day 253, up to 56 days post last dose in RI Period or up to first dose in LTE, whichever occurred earlier.
RI Period; Mean Seated Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) During Period III
Time frame: Days 169, 197, 225, and 253
RI Period; Mean Heart Rate (HR) During Period III
Time frame: Days 169, 197, 225, and 253
RI Period; Mean Temperature (T) During Period III
Time frame: Days 169, 197, 225, and 253
Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ELISA by RI Treatment Groups
Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ELISA.
Time frame: Day 197 through Day 253
Short Term; Abatacept Serum Concentration by Immunogenicity Status as Measured by ECL by RI Treatment Groups
Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ECL.
Time frame: Day 197 through Day 253
ST; Number of Participants Positive for Anti-nuclear Antibody (ANA), Anti-double Stranded DNA Antibody (dsDNA), or Rheumatoid Factor (RF) at Day 253 According to Baseline Status (Negative at Baseline or Positive at Baseline) by DBW Treatment Groups
Venous blood was collected and tested for anti-nuclear antibodies, anti-dsDNA antibodies, and rheumatoid factor. ANA were detected by means of immunofluorescent antibodies. An anti-DNA radioimmunoassay was used for detection of anti-dsDNA antibodies (Diagnostic Products Corporation). RF was measured by an immunoturbidimetric assay (Roche Tina-Quant). Determinations of antibody or RF status were made at baseline and Day 253.
Time frame: Baseline, Day 253
LTE: DAS28-CRP Mean Change From Baseline (Day 1) Over Time - All Participants Treated in LTE
DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. DAS28-CRP has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
Time frame: For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
LTE: Percent of Participants Who Achieved Clinical Remission in the Long Term Extension - All Participants Treated in LTE
DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. Clinical remission=DAS28-CRP score\<2.6. Percent=Number of participants meeting remission divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available (NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
Time frame: For Period I non-responders: as of Study Day 85 and up to Study Day 1821. For ST completers: as of Study Day 253 and up to Study Day 1821
LTE: Percent of Participants With Low Disease Activity in Long Term Extension: All Participants Treated in LTE
DAS28:continuous disease measure composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. Low disease activity score: ≤ 3.2. Percent=Number of participants with Low Disease Activity divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
Time frame: For Period 1 non-responders: as of Study Day 85 and up to Day 1821. For ST completers: as of Study Day 253 and up to Day 1821.
LTE: Percent of Participants With HAQ Response Over Time - All Participants Treated in LTE
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index (DI) was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ DI. Percent=number of participants with HAQ response divided by number of participants in the analysis. Since Period I Non-responders proceeded directly to the LTE at the end of Period I (Day 85), study days do not represent treatment days.
Time frame: Study Days 1 (Baseline),15, 29, 57, 78, 85, 253, 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1345, 1457, 1541,1625,1709,1821,1905,1989, 2073
LTE: Overall Percentage of Participants With Positive Anti-Abatacept or Anti-CTLA4 Antibody Responses (ECL Method) for On-Treatment Visits, Post Last Dose Visits, and Overall Study - All Participants Treated in LTE
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using electrochemiluminescence (ECL). The percent of participants with a positive abatacept induced immunogenicity response against cytotoxic T-lymphocyte antigen 4 (CTLA4) and possibly immunoglobulin (Ig), or against Ig and/or Junction Region was calculated by number of participants with a positive response divided by number of participants evaluated. Overall for on-treatment includes treatment visits on Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, and 1989.
Time frame: Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, 1989 and 28, 56, 85, 168 days post last dose in LTE
LTE: Number of Participants With Death, Related SAEs, SAEs Leading to Discontinuation, Related AEs, or AEs Leading to Discontinuation During Long Term Extension (LTE)
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. SAEs include hospitalizations for elective surgical procedures.All deaths reported during the LTE including those that occurred \> 56 days after the last dose. Related AE or SAE defined as AE or SAE with Certain, Probable, Possible, or Missing relationship to study medication. All participants who completed the ST period could enter the open label LTE on Day 253; LI Period 1 non-responders could directly enter the LTE.
Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014), up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
LTE: Number of Participants With AEs of Special Interest During LTE
AEs of special interest in LTE are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies, local injection site reaction (pre-specified AEs occurring at the site of SC injection) and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014) up to 56 days post last dose. For ST completers: as of Day 253 and up to completion of LTE (FEB 2014) up to 56 days post last dose.
LTE: Number of Participants With Hematology Values Meeting the Marked Abnormality Criteria During LTE
Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
LTE: Number of Participants With Liver and Kidney Function Values Meeting the Marked Abnormality Criteria During LTE
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
LTE: Number of Participants With Electrolyte Values Meeting the Marked Abnormality Criteria During LTE
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
LTE: Number of Participants With Other Chemistry and Urinalysis Values Meeting the Marked Abnormality Criteria During LTE
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
Time frame: For Period I non-responders: as of Day 85 and up to completion of LTE (FEB 2014). For ST completers: as of Day 253 and up to completion of LTE (FEB 2014). Data included up to 56 days post last dose.
LTE: Mean Seated Systolic Blood Pressure (SBP) During LTE
During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
Time frame: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261,1345, 1457,1541,1625,1709,1821,1905,1989,2073
LTE: Mean Seated Diastolic Blood Pressure (DBP) During LTE
During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
Time frame: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
LTE: Mean Heart Rate (HR) During LTE
During LTE, heart rate was taken in participants while seated, measured in beats per minute (bpm) and was assessed at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
Time frame: Days 337, 365, 449, 533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
LTE: Mean Temperature (T) During LTE
During LTE, temperature was taken in participants while seated, measured in degrees celsius and was assessed at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
Time frame: Days 337, 365, 449,533, 617, 729,813, 897,981, 1093, 1177,1261, 1345, 1457,1541,1625,1709,1821,1905,1989,2073
Participants with Rheumatoid Arthritis (American College of Rheumatology Class I, II or III) were enrolled. Study initiated November 2007. Short Term (ST) results and some long term extension (LTE) results up to a database lock in 2010 were released earlier. Study concluded February 2014. Final LTE results are now included.
| Milestone | Abatacept (ABA) [Lead-In (LI)] | Abatacept (ABA) Double-blind Withdrawal (DBW) | Placebo (PLA) Double Blind Withdrawal (DBW) | ABA With IV PLA Loading Dose in Re-introduction (RI) Period | PLA Switched to ABA With ABA IV Loading Dose in RI Period | PLA Switched to ABA With PLA IV Loading Dose in RI Period | Long Term Extension Abatacept for LI Period Non-responders | Long Term Extension (LTE) Abatacept for Short Term Completers |
|---|---|---|---|---|---|---|---|---|
| Started | 167 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 157 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant withdrew consent | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative reason by sponsor | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Missed 2 consecutive doses of study drug | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Abatacept (ABA) [Lead-In (LI)] | Abatacept (ABA) Double-blind Withdrawal (DBW) | Placebo (PLA) Double Blind Withdrawal (DBW) | ABA With IV PLA Loading Dose in Re-introduction (RI) Period | PLA Switched to ABA With ABA IV Loading Dose in RI Period | PLA Switched to ABA With PLA IV Loading Dose in RI Period | Long Term Extension Abatacept for LI Period Non-responders | Long Term Extension (LTE) Abatacept for Short Term Completers |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 40 | 80 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 39 | 77 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Poor/non-compliance | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Abatacept (ABA) [Lead-In (LI)] | Abatacept (ABA) Double-blind Withdrawal (DBW) | Placebo (PLA) Double Blind Withdrawal (DBW) | ABA With IV PLA Loading Dose in Re-introduction (RI) Period | PLA Switched to ABA With ABA IV Loading Dose in RI Period | PLA Switched to ABA With PLA IV Loading Dose in RI Period | Long Term Extension Abatacept for LI Period Non-responders | Long Term Extension (LTE) Abatacept for Short Term Completers |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 40 | 35 | 44 | 0 | 0 |
| Completed | 0 | 0 | 0 | 40 | 35 | 42 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Participant withdrew consent | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: No longer meets study criteria | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | Abatacept (ABA) [Lead-In (LI)] | Abatacept (ABA) Double-blind Withdrawal (DBW) | Placebo (PLA) Double Blind Withdrawal (DBW) | ABA With IV PLA Loading Dose in Re-introduction (RI) Period | PLA Switched to ABA With ABA IV Loading Dose in RI Period | PLA Switched to ABA With PLA IV Loading Dose in RI Period | Long Term Extension Abatacept for LI Period Non-responders | Long Term Extension (LTE) Abatacept for Short Term Completers |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 37 | 113 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 88 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 25 |
| Withdrew: Participant withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 3 |
| Withdrew: Poor/non-compliance | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 |
Serum samples from all treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using an enzyme-linked immunosorbent assay (ELISA). Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
| percentage of participants | Abatacept in DBW Period | Placebo in DBW Period |
|---|---|---|
| Anti-abatacept (n=37, n=71) | 0 | 1.4 |
| Anti-CTLA4-T (n=38, n=73) | 0 | 8.2 |
| Total (n=38, n=73) | 0 | 9.6 |
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
| percentage of participants | PLA Switched to ABA With ABA IV Loading Dose in RI Period | PLA Switched to ABA With PLA IV Loading Dose in RI Period |
|---|---|---|
| Anti-abatacept (n=32, n=41) | 0 | 0 |
| Anti-CTLA4-T (n=32, n=41) | 0 | 4.9 |
| Total (n=32, n=41) | 0 | 4.9 |
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
| percentage of participants | Abatacept in Lead-In Period |
|---|---|
| Overall on TRT visits: anti-ABA (n=162) | 1.2 |
| Overall on TRT visits: anti-CTLA4 (n=165) | 0 |
| Overall on TRT visits: Total (n=165) | 1.2 |
| Overall post visits: anti-ABA (n=3) | 0 |
| Overall post visits: anti-CTLA4 (n=3) | 0 |
| Overall post visits: Total (n=3) | 0 |
| Overall anti-ABA (n=162) | 1.2 |
| Overall anti-CTLA4 (n=165) | 0 |
| Overall Total (n=165) | 1.2 |
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
| percentage of participants | Abatacept in Lead-In Period |
|---|---|
| Overall onTRT visits CTLA4 and Possibly Ig, n=165 | 1.2 |
| Overall onTRT visits Ig and/or JNC region, n=165 | 0 |
| Overall onTRT visits Total, n=165 | 1.2 |
| Overall post visits CTLA4 and possibly Ig, n=3 | 0 |
| Overall post visits Ig and/or JNC region, n=3 | 0 |
| Overall post visits: Total, n=3 | 0 |
| Overall CTLA4 and possibly Ig, n=165 | 1.2 |
| Overall Ig and/or JNC region, n=165 | 0 |
| Overall Total (n=165) | 1.2 |
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. Samples were obtained during treatment (TRT) visits.
| percentage of participants | Abatacept in DBW Period | Placebo in DBW Period |
|---|---|---|
| Overall on TRT visits: anti-ABA, n=39,78 | 0 | 1.3 |
| Overall on TRT visits anti-CTLA4, n=40,80 | 0 | 7.5 |
| Overall on TRT visits: Total, n=40,80 | 0 | 8.8 |
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
| percentage of participants | ABA in DBW Period | Placebo in DBW Period |
|---|---|---|
| Anti-abatacept (n=38, n=73) | 0 | 0 |
| Anti-CTLA4-T (n=38, n=73) | 2.6 | 2.7 |
| Total (n=38, n=73) | 2.6 | 2.7 |
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
No measurements were reported for this outcome.
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
| percentage of participants | ABA in DBW Period | PLA in DBW Period |
|---|---|---|
| Overall onTRT visits CTLA4 and Possibly Ig,n=40,80 | 0 | 6.3 |
| Overall onTRT visits Ig and/or JNC region, n=40,80 | 0 | 3.8 |
| Overall on TRT visits: Total Abs, n=40,80 | 0 | 10.0 |
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
No measurements were reported for this outcome.
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody.
| percentage of participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Overall onTRT visits: anti-ABA, n=39,77 | 2.6 | 1.3 |
| Overall onTRT visits anti-CTLA4, n=40,78 | 5.0 | 3.8 |
| Overall onTRT visits: Total, n=40,78 | 7.5 | 5.1 |
| Overall post visits: anti-ABA, n=1,4 | 0 | 0 |
| Overall post visits: anti-CTLA4, n=1,4 | 0 | 25.0 |
| Overall post visits: Total, n=1,4 | 0 | 25.0 |
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
| percentage of participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Overall onTRT visits CTLA4 and Possibly Ig,n=40,78 | 0 | 0 |
| Overall onTRT visits Ig and/or JNC region, n=40,78 | 0 | 0 |
| Overall onTRT visits: Total, n=40,78 | 0 | 0 |
| Overall post visits: CTLA4 and possibly Ig, n=1,4 | 100.0 | 25.0 |
| Overall post visits: Ig and/or JNC region, n=1,4 | 0 | 0 |
| Overall post visits: Total, n=1,4 | 100.0 | 25.0 |
Serum samples from Abatacept-treated adult participants with active rheumatoid arthritis (RA) were screened for the presence of drug-specific antibodies using ELISA. Immunogenicity was defined as the presence of a positive anti-abatacept or anti-CTLA4 antibody. ST was defined as the LI Period, the DBW Period, and the RI Period (Days 1-253).
| percentage of participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Overall study onTRT visits: anti-ABA, n=39,78 | 7.7 | 1.3 |
| Overall study onTRT visits anti-CTLA4, n=40,80 | 5.0 | 8.8 |
| Overall study onTRT visits: Total, n=40,80 | 12.5 | 10.0 |
| Overall study post visits: anti-ABA, n=1, 4 | 0 | 0 |
| Overall study post visits: anti-CTLA4, n=1, 4 | 0 | 25.0 |
| Overall study post visits: Total, n=1, 4 | 0 | 25.0 |
| Overall study anti-ABA, n=39, 78 | 7.7 | 1.3 |
| Overall study anti-CTLA4, n=40, 80 | 5.0 | 8.8 |
| Overall study Total, n=40,80 | 12.5 | 10.0 |
ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction (JNC) Category=reactivity against constant regions and/or hinge region of human IgG1. Drug-induced seropositivity was defined as a post-baseline titer higher than Baseline, or any post-baseline positivity if Baseline value was missing or negative.
| percentage of Participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Overall onTRT visits CTLA and possibly Ig,n=40,80 | 0 | 7.5 |
| Overall onTRT visits Ig and/or JNC region,n=40,80 | 0 | 3.8 |
| Overall study onTRT visits: Total, n=40,80 | 0 | 10.0 |
| Overall post visits CTLA4 and possibly Ig,n=1,4 | 100.0 | 25.0 |
| Overall post visits: Ig and/or JNC region, n=1,4 | 0 | 0 |
| Overall study post visits: Total, n=1, 4 | 100.0 | 25.0 |
| Overall study CTLA4 and possibly Ig,n=40,80 | 2.5 | 8.8 |
| Overall study Ig and/or JNC region, n=40, 80 | 0 | 3.8 |
| Overall study Total, n=40,80 | 2.5 | 11.3 |
The DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
| units on a scale | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Day 15, n=38, n=75 | -0.64 ± 0.10 | -0.87 ± 0.08 |
| Day 29, n=40, n=80 | -1.07 ± 0.14 | -1.10 ± 0.09 |
| Day 57, n=40. n=79 | -1.39 ± 0.14 | -1.62 ± 0.11 |
| Day 78, n=33, n=76 | -1.76 ± 0.12 | -1.89 ± 0.10 |
| Day 85, n=40, n=78 | -1.97 ± 0.11 | -1.88 ± 0.11 |
| Day 113, n=39, n=80 | -1.78 ± 0.18 | -1.69 ± 0.12 |
| Day 141, n=38, n=76 | -1.81 ± 0.17 | -1.54 ± 0.14 |
| Day 169, n=38, n=75 | -2.03 ± 0.18 | -1.49 ± 0.14 |
| Day 197, n=40, n=79 | -2.14 ± 0.16 | -1.92 ± 0.13 |
| Day 225, n=39, n=77 | -2.20 ± 0.17 | -2.04 ± 0.13 |
| Day 253, n=39, n=74 | -2.22 ± 0.14 | -2.32 ± 0.12 |
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
| percentage of participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Day 85 CMI , n=40, n=78 | 80 | 76.9 |
| Day 85 LDAS, n=40, n=78 | 67.5 | 62.8 |
| Day 85 Clinical Remission, n=40, n=78 | 35.0 | 37.2 |
| Day 169 CMI , n=38, n=75 | 78.9 | 57.3 |
| Day 169 LDAS, n=38, n=75 | 68.4 | 54.7 |
| Day 169 Clinical Remission, n=38, n=75 | 47.4 | 28.0 |
| Day 253 CMI , n=39, n=74 | 87.2 | 89.2 |
| Day 253 LDAS, n=39, n=74 | 69.2 | 79.7 |
| Day 253 Clinical Remission, n=39, n=74 | 51.3 | 63.5 |
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.
| units on a scale | ABA [DBW] | Placebo (PLA) [DBW] |
|---|---|---|
| Day 15, n=40, n=77 | -0.31 ± 0.06 | -0.30 ± 0.04 |
| Day 29, n=40, n=80 | -0.46 ± 0.05 | -0.35 ± 0.04 |
| Day 57, n=40, n=79 | -0.58 ± 0.09 | -0.51 ± 0.06 |
| Day 78, n=33, n=77 | -0.68 ± 0.10 | -0.59 ± 0.07 |
| Day 85, n=40, n=79 | -0.74 ± 0.09 | -0.63 ± 0.07 |
| Day 113, n=40, n=80 | -0.69 ± 0.08 | -0.61 ± 0.06 |
| Day 141, n=39, n=78 | -0.68 ± 0.10 | -0.52 ± 0.07 |
| Day 169, n=38, n=76 | -0.72 ± 0.11 | -0.50 ± 0.07 |
| Day 197, n=40, n=79 | -0.76 ± 0.09 | -0.66 ± 0.06 |
| Day 225, n=40, n=77 | -0.82 ± 0.10 | -0.70 ± 0.06 |
| Day 253, n=39, n=74 | -0.86 ± 0.09 | -0.72 ± 0.06 |
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ disability Index.
| percentage of Participants | ABA [DB] | PLA [DB] |
|---|---|---|
| Day 15, n=40, n=77 | 47.5 | 42.9 |
| Day 29, n=40, n=80 | 62.5 | 52.5 |
| Day 57, n=40, n=79 | 67.5 | 62.0 |
| Day 78, n=33, n=77 | 66.7 | 67.5 |
| Day 85, n=40, n=79 | 80.0 | 69.6 |
| Day 113, n=40, n=80 | 75.0 | 67.5 |
| Day 141, n=39, n=78 | 69.2 | 62.8 |
| Day 169, n=38, n=76 | 71.1 | 56.6 |
| Day 197, n=40, n=79 | 75.0 | 74.7 |
| Day 225, n=40, n=77 | 80.0 | 76.6 |
| Day 253, n=39, n=74 | 84.6 | 74.3 |
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
| units on a scale | ABA [LI] |
|---|---|
| Day 15, n=150 | -0.72 ± 0.06 |
| Day 29, n=165 | -1.00 ± 0.07 |
| Day 57, n=164 | -1.35 ± 0.08 |
| Day 78, n=143 | -1.39 ± 0.10 |
| Day 85, n=161 | -1.53 ± 0.10 |
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
| percentage of participants | ABA [LI] |
|---|---|
| Day 15, n=150 | 26.0 |
| Day 29, n=165 | 40.6 |
| Day 57, n=164 | 56.1 |
| Day 78, n=143 | 59.4 |
| Day 85, n=161 | 64.6 |
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
| units on a scale | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Day 113, n=39, n=76 | 0.19 ± 0.18 | 0.16 ± 0.11 |
| Day 141 , n=38, n=73 | 0.14 ± 0.17 | 0.35 ± 0.15 |
| Day 169, n=38, n=72 | -0.06 ± 0.19 | 0.40 ± 0.14 |
A participant had an RA flare if at least 2 of the following criteria were met: * Doubling of tender and swollen joint count from Day 78 * Increase in DAS28-CRP score ≥ 1.2 from Day 78 * Prematurely discontinued from Double-blind Withdrawal Period (Period 2) and continued to Re-introduction Period (Period 3)
| percentage of participants | ABA [DB] | PLA [DB] |
|---|---|---|
| Day 85, n=31, n=66 | 0 | 1.5 |
| Day 113, n=33, n=77 | 9.1 | 2.6 |
| Day 141, n=32, n=73 | 6.3 | 6.8 |
| Day 169, n=33, n=74 | 6.1 | 9.5 |
DAS28 is a continuous disease measure composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, the level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. DAS28 has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Clinically meaningful improvement= decrease in DAS28 score of ≥1.2 from baseline.
| units on a scale | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Day 197, n=39, n=33, n=44 | -0.26 ± 0.17 | -0.56 ± 0.17 | -0.50 ± 0.16 |
| Day 225, n=38, n=33, n=42 | -0.31 ± 0.20 | -0.59 ± 0.18 | -0.66 ± 0.17 |
| Day 253, n=38, n=30, n=42 | -0.23 ± 0.16 | -0.93 ± 0.20 | -0.89 ± 0.17 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | ABA [LI] |
|---|---|
| Deaths | 1 |
| SAEs | 3 |
| Related SAEs | 0 |
| SAEs Leading to Discontinuation | 1 |
| AEs | 82 |
| Related AEs | 29 |
| AEs Leading to Discontinuation | 1 |
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
| participants | ABA [LI] |
|---|---|
| Infections and infestations | 42 |
| Malignancies | 0 |
| Autoimmune events (prespecified) | 0 |
| Acute infusional events (prespecified) | 1 |
| Peri-infusional events (prespecified) | 2 |
| Local injection site reactions (prespecified) | 2 |
| Systemic injection reactions (prespecified) | 9 |
Upper Normal Limit (ULN), Lower Normal Limit (LLN), Baseline (BL). Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/ microliter (uL); eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
| participants | ABA [LI] |
|---|---|
| Low HGB | 0 |
| Low hematocrit | 0 |
| Low erythrocytes | 1 |
| Low PLT | 1 |
| High PLT | 0 |
| Low leukocytes | 3 |
| High leukocytes | 4 |
| Low neutrophils+bands | 0 |
| High eosinophils | 1 |
| High basophils | 0 |
| High monocytes | 0 |
| Low lymphocytes | 7 |
| High lymphocytes | 0 |
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
| participants | ABA [LI] |
|---|---|
| High ALP | 0 |
| High AST | 1 |
| High ALT | 2 |
| High GGT | 0 |
| High bilirubin | 0 |
| High BUN | 1 |
| High creatinine | 3 |
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
| participants | ABA [LI] |
|---|---|
| Low Na | 0 |
| High Na | 0 |
| Low K | 0 |
| High K | 0 |
| Low Cl | 0 |
| High Cl | 0 |
| Low Ca | 0 |
| High Ca | 0 |
| Low P | 1 |
| High P | 1 |
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*upper limits of normal (ULN),or if BL\< lower limits of normal (LLN) then use 0.8\*BL or \> upper limits of normal (ULN),or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>ULN,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis: Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells (RBCs), White Blood Cells (WBCs):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
| participants | ABA [LI] |
|---|---|
| Low Glu (n=167) | 9 |
| High Glu (n=167) | 4 |
| Low fasting Glu (n=92) | 3 |
| High fasting glucose (n=92) | 0 |
| Low protein (n=167) | 1 |
| High protein (n=167) | 1 |
| Low Albumin (n=167) | 0 |
| High uric acid (n=167) | 0 |
| High urine protein (n=167) | 3 |
| High urine Glu (n=167) | 3 |
| High urine blood (n=167) | 17 |
| High leukocyte esterase (n=46) | 9 |
| High urine RBC (n=44) | 7 |
| High urine WBC (n=63) | 26 |
Blood pressure was taken in participants while seated and measured in millimeters of mercury (mmHg). Pressures were assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
| mmHg | ABA [LI] |
|---|---|
| Day 1 SBP before infusion (n=160) | 125.0 ± 18.42 |
| Day 15 SBP before injection (n=156) | 122.3 ± 14.55 |
| Day 29 SBP before injection (n=161) | 122.0 ± 14.02 |
| Day 57 SBP before injection (n=157) | 121.4 ± 14.87 |
| Day 78 SBP before injection (n=157) | 120.3 ± 14.38 |
| Day 85 SBP before injection (n=159) | 122.0 ± 15.19 |
| Day 1 DBP before infusion (n=160) | 76.0 ± 10.88 |
| Day 15 DBP before injection (n=156) | 75.8 ± 9.63 |
| Day 29 DBP before injection (n=161) | 76.1 ± 9.43 |
| Day 57 DBP before injection (n=157) | 75.7 ± 9.82 |
| Day 78 DBP before injection (n=157) | 75.4 ± 10.29 |
| Day 85 DBP before injection (n=159) | 75.2 ± 9.45 |
Heart rate was taken in participants while seated and measured in beats per minute (bpm). Heart rate was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
| bpm | ABA [LI] |
|---|---|
| Day 1 HR before infusion (n=167) | 73.9 ± 9.78 |
| Day 15 HR before injection (n=160) | 76.0 ± 7.91 |
| Day 29 HR before injection (n=166) | 75.5 ± 9.03 |
| Day 57 HR before injection (n=164) | 75.5 ± 8.95 |
| Day 78 HR before injection (n=158) | 75.1 ± 7.78 |
| Day 85 HR before injection (n=160) | 74.7 ± 8.64 |
Temperature was taken in participants while seated and measured in degrees celsius. Temperature was assessed at screening, at baseline on Day 1 prior to infusion of IV abatacept, at 30 and 60 minutes after IV infusion of abatacept on Day 1, and at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
| degrees Celsius | ABA [LI] |
|---|---|
| Day 1 T before infusion (n=167) | 36.39 ± 0.387 |
| Day 15 T before injection (n=160) | 36.34 ± 0.351 |
| Day 29 T before injection (n=166) | 36.39 ± 0.371 |
| Day 57 T before injection (n=164) | 36.38 ± 0.329 |
| Day 78 T before injection (n=158) | 36.33 ± 0.333 |
| Day 85 T before injection (n=160) | 36.35 ± 0.368 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | ABA [DBW] | Placebo (PLA) [DBW] |
|---|---|---|
| Deaths | 0 | 2 |
| SAEs | 0 | 2 |
| Related SAEs | 0 | 0 |
| AEs Leading to Discontinuation | 0 | 0 |
| AEs | 13 | 29 |
| Related AEs | 2 | 9 |
| AEs Leading to Discontinuation | 0 | 0 |
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
| participants | ABA [DBW] | Placebo (PLA) [DBW] |
|---|---|---|
| Infections and infestations | 5 | 7 |
| Malignancies | 0 | 0 |
| Autoimmune disorders (prespecified) | 0 | 0 |
| Acute infusional events (prespecified) | 0 | 0 |
| Peri-infusional events (prespecified) | 0 | 0 |
| Local injection site reactions (prespecified) | 0 | 0 |
| Systemic injection reactions (prespecified) | 1 | 1 |
Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
| participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Low HGB (n=40, n=80) | 0 | 0 |
| Low hematocrit (n=39, n=79) | 0 | 0 |
| Low erythrocytes (n=40, n=80) | 0 | 0 |
| Low PLT (n=40, n=80) | 0 | 0 |
| High PLT (n=40, n=80) | 0 | 0 |
| Low leukocytes (n=40, n=80) | 0 | 1 |
| High leukocytes (n=40, n=80) | 0 | 0 |
| Low neutrophils+bands (n=40, n=80) | 0 | 0 |
| High eosinophils (n=40, n=80) | 0 | 2 |
| High basophils (n=40, n=80) | 0 | 0 |
| High monocytes (n=40, n=80) | 0 | 0 |
| Low lymphocytes (n=40, n=80) | 2 | 4 |
| High lymphocytes (n=40, n=80) | 0 | 0 |
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
| participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| High ALP | 0 | 0 |
| High AST | 0 | 0 |
| High ALT | 1 | 0 |
| High GGT | 2 | 0 |
| High bilirubin | 0 | 0 |
| High BUN | 0 | 0 |
| High creatinine | 0 | 1 |
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
| participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Low Na | 0 | 0 |
| High Na | 0 | 0 |
| Low K | 0 | 0 |
| High K | 0 | 0 |
| Low Cl | 0 | 0 |
| High Cl | 0 | 0 |
| Low Ca | 0 | 0 |
| High Ca | 0 | 0 |
| Low P | 0 | 0 |
| High P | 0 | 0 |
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
| participants | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Low Glu (n=40, n=80) | 2 | 5 |
| High Glu (n=40, n=80) | 1 | 3 |
| Low fasting Glu (n=27, n=51) | 0 | 1 |
| High fasting Glu (n=27, n=51) | 0 | 1 |
| Low total protein (n=40, n=80) | 0 | 0 |
| High total protein (n=40, n=80) | 0 | 0 |
| Low albumin (n=40, n=80) | 0 | 0 |
| High uric acid (n=40, n=80) | 0 | 0 |
| High urine protein (n=40, n=80) | 1 | 0 |
| High urine Glu (n=40, n=80) | 0 | 1 |
| High urine blood (n=40, n=80) | 3 | 10 |
| High leukocyte esterase (n=10, n=21) | 1 | 4 |
| High urine RBC (n=13, n=23) | 1 | 5 |
| High urine WBC (n=15, n=28) | 6 | 12 |
Blood pressures were taken in participants while seated, just prior to study drug injection, and measured in millimeters of mercury (mmHg).
| mm mercury (Hg) | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Day 113 SBP before injection (n=39, n=78) | 119.4 ± 13.29 | 120.4 ± 15.60 |
| Day 141 SBP before injection (n=39, n=76) | 120.3 ± 12.73 | 121.2 ± 14.98 |
| Day 169 SBP before injection (n=40, n=80) | 119.6 ± 13.87 | 119.4 ± 14.11 |
| Day 113 DBP before injection (n=39, 78) | 74.2 ± 10.44 | 74.4 ± 9.34 |
| Day 141 DBP before injection (n=39, n=76) | 76.3 ± 10.46 | 76.0 ± 10.60 |
| Day 169 DBP before injection (n=40, n=80) | 74.0 ± 9.51 | 74.7 ± 8.94 |
Heart Rate was taken in participants while seated, just prior to study drug injection, and measured in beats per minute (bpm)
| beats per minute (bpm) | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Day 113 HR before injection (n=40, n=78) | 75.8 ± 8.07 | 73.9 ± 8.39 |
| Day 141 HR before injection (n=39, n=76) | 75.9 ± 9.35 | 74.5 ± 8.45 |
| Day 169 HR before injection (n=40, n=80) | 73.8 ± 8.19 | 74.2 ± 8.50 |
Participants were seated and temperature taken just prior to study drug injection.
| degrees Celsius | ABA [DBW] | PLA [DBW] |
|---|---|---|
| Day 113 T before infusion (n=40, n=78) | 36.34 ± 0.488 | 36.44 ± 0.370 |
| Day 141 T before injection (n=39, n=76) | 36.31 ± 0.355 | 36.36 ± 0.347 |
| Day 169 T before injection (n=40, n=80) | 36.38 ± 0.364 | 36.32 ± 0.373 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event.
| participants | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Deaths | 0 | 0 | 0 |
| SAEs | 0 | 0 | 1 |
| Related SAEs | 0 | 0 | 0 |
| SAEs Leading to Discontinuation | 0 | 0 | 0 |
| AEs | 15 | 17 | 16 |
| Related AEs | 1 | 4 | 4 |
| AEs Leading to Discontinuation | 0 | 0 | 0 |
AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies; acute infusional AEs (pre-specified AEs occurring within 1 hour of start of infusion), peri-infusional AEs (pre-specified AEs occurring within 24 hours of the start of infusion),local injection site reaction (pre-specified AEs occurring at the site of SC injection)and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
| participants | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Infections and infestations | 7 | 8 | 7 |
| Malignancies | 0 | 0 | 0 |
| Autoimmune disorders (prespecified) | 0 | 0 | 0 |
| Acute infusional events (prespecified) | 0 | 0 | 0 |
| Peri-infusional events (prespecified) | 0 | 0 | 1 |
| Local injection site reactions (prespecified) | 0 | 0 | 0 |
| Systemic injection reactions (prespecified) | 0 | 0 | 1 |
Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
| participants | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Low HGB | 0 | 0 | 0 |
| Low hematocrit | 0 | 0 | 0 |
| Low erythrocytes | 0 | 0 | 0 |
| Low PLT | 0 | 0 | 0 |
| High PLT | 0 | 0 | 0 |
| Low leukocytes | 0 | 0 | 0 |
| High leukocytes | 0 | 1 | 0 |
| Low neutrophils+bands | 0 | 0 | 0 |
| High eosinophils | 0 | 0 | 0 |
| High basophils | 0 | 0 | 0 |
| High monocytes | 0 | 0 | 0 |
| Low lymphocytes | 2 | 0 | 0 |
| High lymphocytes | 0 | 0 | 0 |
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
| participants | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| High ALP | 0 | 0 | 0 |
| High AST | 0 | 0 | 0 |
| High ALT | 2 | 0 | 0 |
| High GGT | 1 | 0 | 0 |
| High bilirubin | 0 | 0 | 0 |
| High BUN | 0 | 0 | 0 |
| High creatinine | 0 | 0 | 0 |
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
| participants | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Low Na | 0 | 0 | 0 |
| High Na | 0 | 0 | 0 |
| Low K | 0 | 0 | 1 |
| High K | 0 | 0 | 0 |
| Low Cl | 0 | 0 | 0 |
| High Cl | 0 | 0 | 0 |
| Low Ca | 0 | 0 | 0 |
| High Ca | 0 | 0 | 0 |
| Low P | 0 | 1 | 0 |
| High P | 0 | 0 | 0 |
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
| participants | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Low Glu (n=40, n=35, n=44) | 1 | 1 | 1 |
| High Glu (n=40, n=35, n=44) | 0 | 1 | 0 |
| Low fasting Glu (n=27, n=20, n=28) | 1 | 0 | 0 |
| High fasting glucose (n=27, n=20, n=28) | 0 | 0 | 0 |
| Low total protein (n=40, n=35, n=44) | 0 | 0 | 0 |
| High total protein (n=40, n=35, n=44) | 0 | 0 | 0 |
| Low albumin (n=40, n=35, n=44) | 0 | 0 | 0 |
| High uric acid (n=40, n=35, n=44) | 0 | 0 | 0 |
| High urine protein (n=40, n=35, n=44) | 0 | 0 | 1 |
| High urine glucose (n=40, n=34, n=44) | 0 | 0 | 0 |
| High urine blood (n=40, n=35, n=44) | 6 | 4 | 7 |
| High leukocyte esterase (n=14, n=8, n=7) | 4 | 2 | 1 |
| High urine RBC (n=17, n=14, n=15) | 6 | 3 | 6 |
| High urine WBC (n=19, n=15, n=15) | 6 | 5 | 4 |
| mm mercury (Hg) | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Day 169 SBP before infusion (n=39, n=35, n=44) | 121.3 ± 15.81 | 116.6 ± 14.78 | 118.9 ± 13.32 |
| Day 197 SBP before injection (n=40, n=35, n=43) | 119.1 ± 14.07 | 118.4 ± 15.62 | 121.0 ± 14.45 |
| Day 225 SBP before injection (n=40, n=35, n=42) | 117.8 ± 14.19 | 118.8 ± 16.55 | 121.0 ± 16.88 |
| Day 253 SBP before injection (n=40, 35, n=43) | 118.3 ± 15.00 | 116.1 ± 14.86 | 120.3 ± 16.01 |
| Day 169 DBP before infusion (n=39, n=35, n=44) | 74.7 ± 10.46 | 73.5 ± 9.61 | 74.9 ± 9.15 |
| Day 197 DBP before injection (n=40, n=35, n=43) | 72.9 ± 9.24 | 71.6 ± 7.66 | 74.9 ± 9.51 |
| Day 225 DBP before injection (n=40, n=35, n=42) | 73.6 ± 10.56 | 73.7 ± 7.84 | 75.5 ± 10.65 |
| Day 253 DBP before injection (n=40, n=35, n=44) | 74.7 ± 11.24 | 71.5 ± 9.92 | 76.3 ± 11.02 |
| beats per minute (bpm) | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Day 169 HR before infusion (n=40, n=35, n=44) | 73.4 ± 8.54 | 73.8 ± 10.13 | 74.1 ± 9.35 |
| Day 197 HR before injection (n=40, n=35, n=43) | 73.1 ± 7.52 | 75.1 ± 7.25 | 70.9 ± 8.87 |
| Day 225 HR before injection (n=40, n=35, n=42) | 73.2 ± 7.0 | 73.9 ± 7.43 | 73.2 ± 7.60 |
| Day 253 HR before injection (n=40, n=35, n=43) | 73.6 ± 8.53 | 74.4 ± 7.87 | 74.3 ± 9.36 |
| degrees Celsius | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Day 169 T before infusion (n=40, n=35, n=44) | 36.32 ± 0.423 | 36.29 ± 0.473 | 36.26 ± 0.396 |
| Day 197 T before injection (n=40, n=35, n=43) | 36.39 ± 0.405 | 36.37 ± 0.424 | 36.35 ± 0.354 |
| Day 225 T before injection (n=40, n=35, n=42) | 36.27 ± 0.375 | 36.38 ± 0.444 | 36.36 ± 0.320 |
| Day 253 T before injection (n=40, n=34, n=42) | 36.28 ± 0.473 | 36.32 ± 0.587 | 36.33 ± 0.383 |
Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ELISA.
| ug/mL | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Day 197 seropositive (n=2, n=1, n=1) | 39.17 ± 10.510 | 33.73 ± NA | 18.05 ± NA |
| Day 197 seronegative (n=33, n=32, n=40) | 34.45 ± 10.578 | 35.67 ± 10.365 | 22.76 ± 8.740 |
| Day 225 seropositive (n=0, n=1, n=1) | NA ± NA | 34.18 ± NA | 21.69 ± NA |
| Day 225 seronegative (n=36, n=29, n=41) | 27.86 ± 9.514 | 31.70 ± 10.635 | 29.24 ± 13.897 |
| Day 253 seropositive (n=1, n=0, n=2) | 29.49 ± NA | NA ± NA | 26.23 ± 0.776 |
| Day 253 seronegative (n=34, n=30, n=39) | 30.17 ± 9.856 | 28.26 ± 10.211 | 26.80 ± 10.547 |
Pharmacokinetics is a branch of pharmacology concerned with the rate at which drugs are absorbed, distributed, metabolized, and eliminated by the body. Cmin=minimum observed plasma concentration of single-dose abatacept. Cmin for each participant was listed by study visit and immunogenicity status (seropositive vs. seronegative) was determined by ECL.
| ug/mL | ABA With IV PLA Loading Dose [RI] | PLA Switched to ABA With ABA IV Loading Dose [RI] | PLA Switched to ABA With PLA IV Loading Dose [RI] |
|---|---|---|---|
| Day 197 seropositive (n=0, n=0, n=0) | NA ± NA | NA ± NA | NA ± NA |
| Day 197 seronegative (n=35, n=33, n=41) | 34.72 ± 10.479 | 35.61 ± 10.207 | 22.65 ± 8.662 |
| Day 225 seropositive (n=0, n=0, n=0) | NA ± NA | NA ± NA | NA ± NA |
| Day 225 seronegative (n=36, n=30, n=42) | 27.86 ± 9.514 | 31.79 ± 10.460 | 29.06 ± 13.776 |
| Day 253 seropositive (n=0, n=0, n=0) | NA ± NA | NA ± NA | NA ± NA |
| Day 253 seronegative (n=36, n=30, n=42\) | 29.75 ± 9.872 | 28.26 ± 10.211 | 26.28 ± 10.645 |
Venous blood was collected and tested for anti-nuclear antibodies, anti-dsDNA antibodies, and rheumatoid factor. ANA were detected by means of immunofluorescent antibodies. An anti-DNA radioimmunoassay was used for detection of anti-dsDNA antibodies (Diagnostic Products Corporation). RF was measured by an immunoturbidimetric assay (Roche Tina-Quant). Determinations of antibody or RF status were made at baseline and Day 253.
| participants | ABA [DBW] | Placebo (PLA) [DBW] |
|---|---|---|
| BL ANA negative (n=27, n=57) | 1 | 3 |
| BL ANA positive (n=11, 18) | 5 | 10 |
| BL dsDNA negative (n=33, n=63) | 1 | 2 |
| BL dsDNA positive (n=3, n=6) | 2 | 3 |
| BL RF negative (n=6, n=10) | 0 | 0 |
| BL RF positive (n=34, n=64) | 34 | 63 |
DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. DAS28-CRP has numeric thresholds defining high disease activity (\> 5.1), low disease activity (≤ 3.2) and remission (\< 2.6). Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
| units on a scale | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Study Day 15; Treatment Day 15 (n=31, 106) | -0.48 ± 0.14 | -0.79 ± 0.06 |
| Study Day 85; Treatment Day 85 (n=36, 112) | -0.35 ± 0.21 | -1.91 ± 0.09 |
| Study Day 253; Treatment Day 85 (n=0, n=109) | NA ± NA | -2.29 ± 0.09 |
| Study Day 337; Treatment Day 169 (n=34,n=113) | -1.51 ± 0.16 | -2.34 ± 0.09 |
| Study Day 365; Treatment Day 197 (n=31, n=110) | -1.83 ± 0.19 | -2.23 ± 0.10 |
| Study Day 533; Treatment Day 365 (n=32, n=106) | -1.86 ± 0.19 | -2.28 ± 0.12 |
| Study Day 729; Treatment Day 561 (n=30, n=106 | -1.81 ± 0.19 | -2.16 ± 0.12 |
| Study Day 1093; Treatment Day 925 (n=26, n=98) | -1.94 ± 0.18 | -2.12 ± 0.12 |
| Study Day 1261; Treatment Day 1093 (n=25, n=96) | -1.70 ± 0.15 | -2.20 ± 0.13 |
| Study Day 1821; Treatment Day 1653 (n=20, n=67) | -1.86 ± 0.20 | -2.55 ± 0.14 |
DAS28=continuous disease measure composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28, level of serum reactant protein CRP, and participant global assessment of disease activity measured on a visual analogue scale. Clinical remission=DAS28-CRP score\<2.6. Percent=Number of participants meeting remission divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available (NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
| percentage of participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Study Day 85 (n=36, n=112) | 11.1 | 36.6 |
| Study Day 253 (n=0, n=109) | NA | 59.6 |
| Study Day 337 (n=34, n=113) | 50.0 | 59.3 |
| Study Day 729 (n=30, n=106) | 53.3 | 54.7 |
| Study Day 1093 (n=26, 90) | 73.1 | 51.0 |
| Study Day 1261 (n=25, n=96) | 48.0 | 59.4 |
| Study Day 1821 (n=20, n=67) | 60.0 | 59.7 |
DAS28:continuous disease measure composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, level of the serum reactant protein CRP, and participant global assessment of disease activity measure on a visual analogue scale. Low disease activity score: ≤ 3.2. Percent=Number of participants with Low Disease Activity divided by number of participants evaluated. Last day of ST is Day 85 for Period I Nonresponders and Day 253 for ST Completers . Data are not available(NA) for the period from Day 113 to Day 253 for Period 1 non-responders. Note: Day 85 and Day 337 assessments for the Period I Nonresponder cohort in fact represent consecutive assessments with an interval of approximately 1 month. For Period I nonresponder, study days do not represent treatment days. Study Day 337 for a Period I nonresponder actually corresponds to that participant's Treatment Day 169.
| percentage of participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Study Day 85 (n=36, n=112) | 27.8 | 66.1 |
| Study Day 253 (n=0, n=109) | NA | 75.2 |
| Study Day 337 (n=34, n=113) | 67.6 | 76.1 |
| Study Day 729 (n=30, n=106) | 73.3 | 73.6 |
| Study Day 1093 (n=26, n=98) | 80.8 | 67.3 |
| Study Day 1261 (n=25, n=96) | 68.0 | 75.0 |
| Study Day 1821 (n=20, n=67) | 80.0 | 88.1 |
The disability section of the full HAQ includes 20 questions to assess physical functions in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip and common activities. The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction. A disability index (DI) was calculated by summing the worst scores in each domain and dividing by the number of domains answered. Clinically meaningful HAQ response=an improvement of at least 0.3 units from baseline in HAQ DI. Percent=number of participants with HAQ response divided by number of participants in the analysis. Since Period I Non-responders proceeded directly to the LTE at the end of Period I (Day 85), study days do not represent treatment days.
| percentage of participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Study Day 15; Treatment Day 15 (n=34, n=110) | 20.6 (7.0 to 34.2) | 44.5 (35.3 to 53.8) |
| Study Day 29; Treatment Day 29 (n=36, n=113) | 27.8 (13.1 to 42.4) | 56.6 (47.5 to 65.8) |
| Study Day 57; Treatment Day 57 (n=36, n=112) | 44.4 (28.2 to 60.7) | 64.3 (55.4 to 73.2) |
| Study Day 78; Treatment Day 78 (n=34, n=103) | 41.2 (24.6 to 57.7) | 68.0 (58.9 to 77.0) |
| Study Day 85; Treatment Day 85 (n=37, n=112) | 40.5 (24.7 to 56.4) | 74.1 (66.0 to 82.2) |
| Study Day 253; Treatment Day 85 (n=0, n=109) | NA (NA to NA) | 78.0 (70.2 to 85.8) |
| Study Day 337; Treatment Day 169 (n=34, n=113) | 50.0 (33.2 to 66.8) | 79.6 (72.2 to 87.1) |
| Study Day 365; Treatment Day 197 (n=32, n=111) | 53.1 (35.8 to 70.4) | 78.4 (70.7 to 86.0) |
| Study Day 449; Treatment Day 281 (n=32, n=109) | 56.3 (39.1 to 73.4) | 73.4 (65.1 to 81.7) |
| Study Day 533; Treatment Day 365 (n=32, n=108) | 59.4 (42.4 to 76.4) | 72.2 (63.8 to 80.7) |
| Study Day 617; Treatment Day 449 (n=31, n=107) | 54.8 (37.3 to 72.4) | 70.1 (61.4 to 78.8) |
| Study Day 729; Treatment Day 561 (n=30, n=107) | 60.0 (42.5 to 77.5) | 70.1 (61.4 to 78.8) |
| Study Day 813; Treatment Day 645 (n=30, n=106) | 53.3 (35.5 to 71.2) | 71.7 (63.1 to 80.3) |
| Study Day 897; Treatment Day 729 (n=30, n=103) | 50.0 (32.1 to 67.9) | 76.7 (68.5 to 84.9) |
| Study Day 981; Treatment Day 813 (n=29, n=100) | 44.8 (26.7 to 62.9) | 73.0 (64.3 to 81.7) |
| Study Day 1093; Treatment Day 925 (n=28, n=99) | 50.0 (31.5 to 68.5) | 73.7 (65.1 to 82.4) |
| Study Day 1177; Treatment Day 1009 (n=26, n=99) | 61.5 (42.8 to 80.2) | 68.7 (59.6 to 77.8) |
| Study Day 1261; Treatment Day 1093 (n=25, n=97) | 60.0 (40.8 to 79.2) | 70.1 (61.0 to 79.2) |
| Study Day 1345; Treatment Day 1177 (n=25, n=89) | 64.0 (45.2 to 82.8) | 70.8 (61.3 to 80.2) |
| Study Day 1457; Treatment Day 1289 (n=24, n=79) | 66.7 (47.8 to 85.5) | 72.2 (62.3 to 82.0) |
| Study Day 1541; Treatment Day 1373 (n=21, n=75) | 61.9 (41.1 to 82.7) | 69.3 (58.9 to 79.8) |
| Study Day 1625; Treatment Day 1457 (n=21, n=73) | 52.4 (31.0 to 73.7) | 74.0 (63.9 to 84.0) |
| Study Day 1709; Treatment Day 1541 (n=20, n=71) | 60.0 (38.5 to 81.5) | 74.6 (64.5 to 84.8) |
| Study Day 1821; Treatment Day 1653 (n=20, n=68) | 65.0 (44.1 to 85.9) | 73.5 (63.0 to 84.0) |
| Study Day 1905; Treatment Day 1737 (n=19, n=5) | 63.2 (41.5 to 84.8) | 80.0 (44.9 to 100.0) |
| Study Day 1989; Treatment Day 1821 (n=19, n=0) | 68.4 (47.5 to 89.3) | NA (NA to NA) |
| Study Day 2073; Treatment Day 1905 (n=5, n=0) | 100.0 (100.0 to 100.0) | NA (NA to NA) |
Serum samples from Abatacept-treated adult participants with active RA were screened for the presence of drug-specific antibodies using electrochemiluminescence (ECL). The percent of participants with a positive abatacept induced immunogenicity response against cytotoxic T-lymphocyte antigen 4 (CTLA4) and possibly immunoglobulin (Ig), or against Ig and/or Junction Region was calculated by number of participants with a positive response divided by number of participants evaluated. Overall for on-treatment includes treatment visits on Days 337, 365, 449, 533, 617, 729, 813, 897, 981, 1093, 1177, 1261, 1457, 1625, 1821, and 1989.
| percentage of participants | LTE Abatacept for All Participants |
|---|---|
| Overall Study (n=149) | 20.1 |
| Overall on Treatment Visit Days (n=147) | 15.6 |
| 28 Days post last dose (n=110) | 7.3 |
| 56 Days post last dose (n=16) | 6.3 |
| 85 Days post last dose (n=103) | 7.8 |
| 168 Days post last dose (n=21) | 23.8 |
| Overall Post Visits (n=126) | 12.7 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. SAEs include hospitalizations for elective surgical procedures.All deaths reported during the LTE including those that occurred \> 56 days after the last dose. Related AE or SAE defined as AE or SAE with Certain, Probable, Possible, or Missing relationship to study medication. All participants who completed the ST period could enter the open label LTE on Day 253; LI Period 1 non-responders could directly enter the LTE.
| participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Deaths | 1 | 6 |
| Related SAEs | 0 | 3 |
| SAEs Leading to Discontinuation | 1 | 5 |
| Related AEs | 9 | 45 |
| AEs Leading to Discontinuation | 2 | 5 |
AEs of special interest in LTE are those AEs that may be associated with the use of immunomodulatory drugs, including all infections and opportunistic infections; autoimmune disorders; malignancies, local injection site reaction (pre-specified AEs occurring at the site of SC injection) and systemic injection site reactions (pre-specified systemic AEs such as hypersensitivity reactions occurring within 24 hours of SC injection)
| participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Infections and infestations | 23 | 78 |
| Malignancies | 1 | 3 |
| Autoimmune disorders (prespecified) | 3 | 8 |
| Local injection site reactions (prespecified) | 0 | 3 |
| Systemic injection reactions (prespecified) | 3 | 11 |
Marked abnormality criteria are: Hemoglobin (HGB): \>3 g/dL decrease from BL; Hematocrit: \<0.75 \* BL; Erythrocytes: \<0.75 \* BL; Platelets (PLT): \<0.67 \* LLN/\>1.5 \* ULN, or if BL \< LLN then use \<0.5 \* BL and \<100,000 mm\^3; Leukocytes: \<0.75 \* LLN/ \>1.25 \* ULN, or if BL\<LLN then use \<0.8 \* BL or \>ULN, or if BL\>ULN then use \>1.2 \* BL or \<LLN; neutrophils+bands: \<1.0 \* 10\^3 cells/uL; eosinophils: \>0.750 \* 10\^3 cells/uL; basophils: \> 400 mm\^3; monocytes: \>2000 mm\^3; lymphocytes: \<0.750 \* 10\^3 cells/uL/ \>7.50 \* 10\^3 cells/uL.
| participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Low HGB | 1 | 4 |
| Low hematocrit | 0 | 2 |
| Low erythrocytes | 0 | 1 |
| Low PLT | 0 | 1 |
| Low leukocytes | 1 | 5 |
| High leukocytes | 0 | 6 |
| Low neutrophils+bands | 0 | 2 |
| High eosinophils | 3 | 14 |
| Low lymphocytes | 5 | 9 |
Marked abnormality criteria: Alkaline phosphatase (ALP): \>2\* ULN, or if BL\>ULN then use \>3\* BL; aspartate aminotransferase (AST): \>3\* ULN, or if BL\>ULN then use \>4\* BL; alanine aminotransferase (ALT): \>3\* ULN, or if BL\>ULN then use \>4\* BL; G-Glutamyl transferase (GGT): \>2\* ULN, or if BL\>ULN then use \>3\* BL; Bilirubin: \>2\* ULN, or if BL\>ULN then use \>4\* BL; blood urea nitrogen (BUN): \>2\* BL; creatinine: \>1.5\* BL
| participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| High AST | 0 | 3 |
| High ALT | 2 | 2 |
| High GGT | 1 | 8 |
| High bilirubin | 0 | 1 |
| High BUN | 0 | 7 |
| High creatinine | 4 | 11 |
Marked abnormality criteria: Sodium (Na): \<0.95\*LLN/ \>1.05\*ULN, or if BL\<LLN then use \<0.95\* BL or \>ULN, or if BL\>ULN then use\>1.05\* BL or \<LLN; potassium (K): \<0.9\* LLN/\>1.1\*ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; (Cl): \<0.9\* LLN/\>1.1\* ULN, or if BL\<LLN then use \<0.9\* BL or \>ULN, or if BL\>ULN then use\>1.1\* BL or \<LLN; calcium (Ca): \<0.8\* LLN/\>1.2\* ULN, or if BL\<LLN then use \<0.75\* BL or \>ULN, or if BL\>ULN then use\>1.25\* BL or \<LLN; phosphorous (P): \<0.75\* LLN/ \>1.25\* ULN, or if BL\<LLN then use 0.67\* BL or \>ULN, or if BL\>ULN then use\>1.33\* BL or \<LLN
| participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| High Na | 1 | 0 |
| Low K | 0 | 3 |
| High Cl | 1 | 0 |
| Low P | 0 | 5 |
| High P | 1 | 0 |
MA criteria: serum glucose (Glu): \<65 mg/dL/\>220 mg/dL;fasting serum Glu: \<0.8\* LLN/\>1.5\*ULN,or if BL\<LLN then use 0.8\*BL or \>ULN,or if BL\>ULN then use \>2.0\*BL or \<LLN;total protein: \<0.9\*LLN/\>1.1\*ULN,or if BL\<LLN then use \<0.9\*BL or \>UNL,or if BL\>UNL then use \>1.1\*BL or \<LLN; albumin: \<0.9\*LLN,or if BL\<LLN then use \<0.75 BL;uric acid: \>1.5\*ULN,or if BL\>ULN then use \>2\*BL. Urinalysis (Urine protein,urine Glu,urine blood,leukocyte esterase,Red Blood Cells \[RBCs\], White Blood Cells \[WBCs\]):Use ≥2 when BL value missing or when pre-dose=0 or 0.5; use ≥3 when pre-dose=1, use ≥4 when pre-dose=2 or 3
| participants | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Low Glu (n=35, n=113) | 6 | 16 |
| High Glu (n=35, n=113) | 1 | 6 |
| Low fasting Glu (n=14, n=75) | 4 | 2 |
| High fasting Glu (n=14, n=75) | 0 | 6 |
| Low total protein (n=35, n=113) | 1 | 0 |
| Low albumin (n=35, n=113) | 1 | 0 |
| High urine protein (n=35, n=113) | 2 | 11 |
| High urine Glu (n=35, n=113) | 1 | 3 |
| High urine blood (n=35, n=113) | 5 | 30 |
| High urine WBC (n=22, n=81) | 12 | 39 |
| High urine RBC (n=16, n=66) | 1 | 27 |
| High leukocyte esterase (n=19, n=67) | 6 | 18 |
During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
| mm Hg | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Day 337 (n=35, n=110) | 125.7 ± 13.76 | 120.8 ± 15.92 |
| Day 365 (n=32, n=108) | 122.7 ± 14.26 | 120.4 ± 15.11 |
| Day 449 (n=32, n=108) | 122.9 ± 15.08 | 119.5 ± 14.88 |
| Day 533 (n=32, n=108) | 123.0 ± 14.48 | 120.7 ± 15.75 |
| Day 617 (n= 30, n=107) | 121.7 ± 13.26 | 118.7 ± 15.30 |
| Day 729 (n=30, n=106) | 122.2 ± 11.77 | 121.5 ± 17.41 |
| Day 813 (n=30, n=101) | 126.6 ± 12.66 | 120.6 ± 15.65 |
| Day 897 (n=30, n=102) | 123.9 ± 11.92 | 122.5 ± 14.92 |
| Day 981 (n=28, n=100) | 123.3 ± 12.23 | 122.9 ± 15.03 |
| Day 1093 (n=26, n=99) | 127.2 ± 18.41 | 123.7 ± 15.11 |
| Day 1177 (n=25, n=96) | 125.8 ± 11.17 | 123.0 ± 15.96 |
| Day 1261 (n=25, n=92) | 124.9 ± 11.04 | 119.7 ± 13.64 |
| Day 1345 (n=24, n=82) | 124.5 ± 13.11 | 121.9 ± 14.49 |
| Day 1457 (n=21, n=79) | 124.1 ± 14.75 | 125.5 ± 18.41 |
| Day 1541 (n=21, n=79) | 126.1 ± 15.06 | 122.3 ± 14.53 |
| Day 1625 (n=21, n=77) | 122.4 ± 9.09 | 120.3 ± 13.76 |
| Day 1709 (n=21, n=74) | 123.0 ± 13.08 | 121.9 ± 14.90 |
| Day 1821 (n=20, n=33) | 125.4 ± 13.22 | 124.3 ± 10.95 |
| Day 1905 (n=18, n=0) | 121.8 ± 13.14 | NA ± NA |
| Day 1989 (n=13, n=0) | 124.6 ± 9.56 | NA ± NA |
| Day 2073 (n=1, n=0) | 113.0 ± 0 | NA ± NA |
During LTE, blood pressure was taken in participants while seated, measured in millimeters of mercury (mmHg) and were assessed at all office visits prior to SC injection of abatacept. Vital signs were also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
| mmHg | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Day 337 (n=35, 110) | 76.3 ± 6.69 | 75.4 ± 11.18 |
| Day 365 (n=32, 108) | 75.1 ± 10.42 | 75.1 ± 8.94 |
| Day 449 (n=32, n=108) | 77.3 ± 9.48 | 73.8 ± 9.12 |
| Day 533 (n=32, n=108) | 75.5 ± 8.43 | 75.4 ± 9.14 |
| Day 617 (n=30, n=107) | 74.2 ± 8.81 | 74.8 ± 9.45 |
| Day 729 (n=30, n=106) | 73.2 ± 8.42 | 76.1 ± 9.86 |
| Day 813 (n=30, n=101) | 75.7 ± 9.39 | 76.4 ± 9.30 |
| Day 897 (n=30, n=102) | 76.8 ± 8.41 | 75.5 ± 9.09 |
| Day 981 (n=28, n=100) | 77.4 ± 6.55 | 76.1 ± 9.67 |
| Day 1093 (n=26, n=99) | 76.7 ± 7.11 | 75.9 ± 9.88 |
| Day 1177 (n=25, n=96) | 76.3 ± 6.32 | 75.9 ± 8.58 |
| Day 1261 (n=25, n=92) | 75.4 ± 8.18 | 75.6 ± 8.59 |
| Day 1345 (n=24, n=82) | 75.3 ± 6.08 | 75.6 ± 9.03 |
| Day 1457 (n=21, n=79) | 75.6 ± 9.18 | 77.1 ± 10.04 |
| Day 1541 (n=21, n=79) | 76.9 ± 8.14 | 76.0 ± 9.15 |
| Day 1625 (n=21, n=77) | 77.2 ± 5.89 | 74.9 ± 9.01 |
| Day 1709 (n=21, n=74) | 75.0 ± 9.47 | 75.4 ± 9.09 |
| Day1821 (n=20, n=33) | 76.0 ± 7.99 | 78.3 ± 7.57 |
| Day 1905 (n=18, n=0) | 73.2 ± 7.96 | NA ± NA |
| Day 1989 (n=13, n=0) | 77.0 ± 5.31 | NA ± NA |
| Day 2073 (n=1, n=0) | 69.0 ± 0 | NA ± NA |
During LTE, heart rate was taken in participants while seated, measured in beats per minute (bpm) and was assessed at all office visits prior to SC injection of abatacept. Heart rate was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
| bpm | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Day 337 (n=35, n=110) | 74.3 ± 7.07 | 74.9 ± 8.76 |
| Day 365 (n=32, n=109) | 74.2 ± 7.76 | 75.7 ± 8.45 |
| Day 449 (n=32, n=108) | 74.4 ± 6.62 | 75.7 ± 7.76 |
| Day 533 (n=32, n=108) | 75.8 ± 6.62 | 74.7 ± 8.32 |
| Day 617 (n=30, n=107) | 75.7 ± 6.96 | 76.0 ± 8.35 |
| Day 729 (n=30, n=106) | 74.2 ± 8.60 | 75.1 ± 8.70 |
| Day 813 (n=30, n=103) | 72.4 ± 7.57 | 76.2 ± 9.23 |
| Day 897 (n=30, n=102) | 76.1 ± 7.71 | 76.3 ± 8.15 |
| Day 981 (n=28, n=100) | 74.4 ± 8.00 | 76.5 ± 10.75 |
| Day 1093 (n=26, n=99) | 76.3 ± 8.35 | 75.0 ± 9.20 |
| Day 1177 (n=25, n=97) | 77.6 ± 6.89 | 75.3 ± 9.00 |
| Day 1261 (n=25, n=92) | 75.7 ± 7.97 | 74.4 ± 8.91 |
| Day 1345 (n=24, n=82) | 73.5 ± 8.54 | 73.6 ± 8.62 |
| Day 1457 (n=21, n=79) | 75.0 ± 7.67 | 76.8 ± 7.96 |
| Day 1541 (n=21, n=79) | 77.3 ± 7.34 | 75.1 ± 8.51 |
| Day 1625 (n=21, n=77) | 76.9 ± 7.77 | 75.2 ± 8.12 |
| Day 1709 (n=21, n=74) | 78.7 ± 6.86 | 74.7 ± 8.83 |
| Day 1821 (n=20, n=33) | 79.5 ± 7.80 | 78.2 ± 6.78 |
| Day 1905 (n=18, n=0) | 77.1 ± 8.97 | NA ± NA |
| Day 1989 (n= 13, n=0) | 77.2 ± 9.53 | NA ± NA |
| Day 2073 (n=1, n=0) | 63.0 ± 0 | NA ± NA |
During LTE, temperature was taken in participants while seated, measured in degrees celsius and was assessed at all office visits prior to SC injection of abatacept. Temperature was also assessed 7 days after the last injection of abatacept for participants who were withdrawn prematurely.
| degrees Celsius | LTE Abatacept for LI Period 1 Non-responders | LTE Abatacept for Short Term Completers |
|---|---|---|
| Day 337 (n=35, n=110) | 36.29 ± 0.285 | 36.31 ± 0.370 |
| Day 365 (n=32, n=108) | 36.35 ± 0.370 | 36.30 ± 0.393 |
| Day 449 (n=32, n=108) | 36.40 ± 0.354 | 36.30 ± 0.294 |
| Day 533 (n=32, n=108) | 36.42 ± 0.358 | 36.30 ± 0.312 |
| Day 617 (n=30, n=106) | 36.38 ± 0.248 | 36.37 ± 0.316 |
| Day 729 (n=30, n=106) | 36.47 ± 0.252 | 36.27 ± 0.332 |
| Day 813 (n=30, n=103) | 36.49 ± 0.284 | 36.30 ± 0.324 |
| Day 897 (n=30, n=102) | 36.44 ± 0.254 | 36.26 ± 0.325 |
| Day 981 (n=28, n=100) | 36.48 ± 0.259 | 36.30 ± 0.295 |
| Day 1093 (n=26, n=99) | 36.35 ± 0.370 | 36.28 ± 0.278 |
| Day 1177 (n=25, n=97) | 36.41 ± 0.277 | 36.24 ± 0.327 |
| Day 1261 (n=25, n=92) | 36.39 ± 0.256 | 36.24 ± 0.276 |
| Day 1345 (n=24,n=82) | 36.29 ± 0.285 | 36.23 ± 0.232 |
| Day 1457 (n=21, n=79) | 36.32 ± 0.253 | 36.23 ± 0.242 |
| Day 1541 (n=21, n=79) | 36.34 ± 0.223 | 36.24 ± 0.198 |
| Day 1625 (n=21, n=77) | 36.37 ± 0.215 | 36.20 ± 0.214 |
| Day 1709 (n=21, n=74) | 36.35 ± 0.178 | 36.24 ± 0.249 |
| Day 1821 (n=20, n=33) | 36.25 ± 0.315 | 36.26 ± 0.228 |
| Day 1905 (n=18, n=0) | 36.37 ± 0.211 | NA ± NA |
| Day 1989 (n=13, n=0) | 36.35 ± 0.139 | NA ± NA |
| Day 2073 (n=1, n=0) | 36.40 ± 0 | NA ± NA |
Collected over Day 1 up to 56 days post last dose, through LTE (for those participating in LTE); Day 1 up to 56 days post last dose until final day of study for Period 1 non-completers.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1 Non-Completers | — | 2/10 (20%) | 6/10 (60%) |
| Period 1 Non-Responders | — | 12/37 (32.4%) | 29/37 (78.4%) |
| Abatacept Received in Period 2 | — | 11/40 (27.5%) | 33/40 (82.5%) |
| Placebo Received in Period 2 | — | 27/80 (33.8%) | 66/80 (82.5%) |
| Event | Period 1 Non-Completers | Period 1 Non-Responders | Abatacept Received in Period 2 | Placebo Received in Period 2 |
|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/10 | 0/37 | 1/40 | 0/80 |
| CellulitisInfections and infestations | 1/10 | 1/37 | 0/40 | 0/80 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/10 | 0/37 | 0/40 | 0/80 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/10 | 2/37 | 0/40 | 3/80 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/10 | 1/37 | 0/40 | 0/80 |
| Vertebral foraminal stenosisMusculoskeletal and connective tissue disorders | 0/10 | 1/37 | 0/40 | 0/80 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/10 | 1/37 | 0/40 | 0/80 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/10 | 1/37 | 0/40 | 0/80 |
| Renal colicRenal and urinary disorders | 0/10 | 1/37 | 0/40 | 0/80 |
| Stress urinary incontinenceRenal and urinary disorders | 0/10 | 1/37 | 0/40 | 0/80 |
| Event | Period 1 Non-Completers | Period 1 Non-Responders | Abatacept Received in Period 2 | Placebo Received in Period 2 |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/10 | 14/37 | 12/40 | 18/80 |
| BronchitisInfections and infestations | 0/10 | 11/37 | 9/40 | 18/80 |
| Urinary tract infectionInfections and infestations | 0/10 | 6/37 | 10/40 | 15/80 |
| InfluenzaInfections and infestations | 0/10 | 9/37 | 5/40 | 14/80 |
| SinusitisInfections and infestations | 1/10 | 6/37 | 6/40 | 16/80 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 1/37 | 6/40 | 6/80 |
| NasopharyngitisInfections and infestations | 1/10 | 4/37 | 6/40 | 8/80 |
| HypertensionVascular disorders | 0/10 | 3/37 | 3/40 | 10/80 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/10 | 1/37 | 5/40 | 6/80 |
| Back painMusculoskeletal and connective tissue disorders | 0/10 | 4/37 | 3/40 | 7/80 |
All Period 1 Non-responders and Period 2 participants who received at least one dose of abatacept during the study were summarized.
| Age, Continuous(years) | Period 1 Non-Responders | Abatacept Received in Period 2 | Placebo Received in Period 2 | Total |
|---|---|---|---|---|
| Mean | 53.4 ± 12.7 | 48.9 ± 14.2 | 49.1 ± 12.8 | 49.8 ± 13.1 |
| Sex: Female, Male(Participants) | Period 1 Non-Responders | Abatacept Received in Period 2 | Placebo Received in Period 2 | Total |
|---|---|---|---|---|
| Female | 30 | 34 | 67 | 131 |
| Male | 7 | 6 | 13 | 26 |
The record gives a start of Nov 2007, a primary completion of Dec 2008 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept